SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Ikuo Hirano, MD, FACG, a professor of medicine at Northwestern University Feinberg School of Medicine, discusses his presentation of a phase 3 study on the efficacy of budesonide oral suspension for eosinophilic esophagitis.
“Currently, there is a large, unmet need for the management of eosinophilic esophagitis,” Hirano told Healio Gastroenterology and Liver Disease. “Our practice, right now, in gastroenterology for taking care of patients with eosinophilic esophagitis consists of using elimination diets, which get rid of common food allergens from our patients. Another strategy is to use proton pump inhibition, which is effective in about 30% to 50% of patients.”
Hirano said the budesonide oral suspension helped reduce symptoms of dysphagia and the histologic, pathologic hallmarks of the disease. Compared with placebo, the oral suspension also improved endoscopic features of EoE.
According to Hirano, this was the largest clinical trial ever conducted in EoE and the first to use a validated patient-reported outcome instrument.
Hirano I, et al. Abstract 1. Presented at: American College of Gastroenterology Annual Meeting; Oct. 25-30, 2019; San Antonio.
Disclosures: Hirano reports consulting for and receiving grant/research support from Allakos, Meritage, Receptos/Celgene, Regeneron and Shire.